US Oncology Research, LLC

1. Genentech, Inc. $3,475,623 925 payments
2. Clovis Oncology, Inc. $2,535,477 350 payments
3. Novocure Inc. $1,072,742 187 payments
4. TG Therapeutics, Inc. $1,042,001 779 payments
5. Merck Sharp & Dohme Corporation $864,094 9 payments
6. Tolmar, Inc. $756,393 406 payments
7. ADC Therapeutics America, Inc. $660,355 122 payments
8. Blueprint Medicines Corporation $562,101 130 payments
9. Hoffmann-La Roche Limited $291,504 83 payments
10. Celgene Corporation $246,976 22 payments

1. A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy (ATHENA) $2,555,754 332 payments
2. Phase III Study of Giredestrant Everolimus VS Everolimus Exemestane in Er Her2 Locally Adv Or MBC $1,352,795 513 payments
3. ULTRA-V: Phase 2/3 Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with Umbralisib and Venetoclax (U2-V) Compared to Ublituximab and Umbralisib (U2) in Subjects with Chronic Lymphocytic Leukemia (CLL) $804,465 432 payments
4. MYLUNG Program $782,867 1 payment
5. Polarix $741,355 259 payments
6. A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer EOC $559,435 5 payments
7. EF-28 Engot -ov50/ INNOVATE-3: Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (TTFields, 200kHz) Concomitant with Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer $537,188 51 payments
8. EF-27 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150lHz) concomitant with gemcitabine and nab-paclitaxel) for front-line treatment of locally-advanced pancreatic adenocarcinoma $403,772 57 payments
9. A Phase 2 Open-label Study of Loncastuximab Tesirine in Combination With Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Patients With Diffuse Large B-cell Lymphoma (DLBCL) (LOTIS-9) $367,669 74 payments
10. A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer KEYNOTE-A18 , ENGOT-cx11,GOG-3047 $304,659 4 payments

1. Patient care $284,743 18 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.